3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
5
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
HRD Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Nivolumab
3
ulixertinib
2
dabrafenib
2
binimetinib
2
Surveys and Questionnaires
2
Sunitinib
2
Ipilimumab
2
Immunoglobulin G
2
Disulfides
2
Cetuximab
2
CTLA-4 Antigen
2
Biopsy
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
temsirolimus
1
selpercatinib
1
sapanisertib
1
repotrectinib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
gallium Ga 68 dotatate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
sacituzumab govitecan
×
30 days
×
Clear all
No trials found.